Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Joseph Henson  (Henson J) 1 Article
Diabetes
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab. 2019;34(3):247-262.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.247
  • 10,242 View
  • 383 Download
  • 52 Web of Science
  • 56 Crossref
AbstractAbstract PDFPubReader   ePub   

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by  
  • Drug‐related sarcopenia as a secondary sarcopenia
    Masafumi Kuzuya
    Geriatrics & Gerontology International.2024; 24(2): 195.     CrossRef
  • Exercise induces tissue-specific adaptations to enhance cardiometabolic health
    Stephen P. Ashcroft, Ben Stocks, Brendan Egan, Juleen R. Zierath
    Cell Metabolism.2024; 36(2): 278.     CrossRef
  • Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes
    Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki
    Obesity Pillars.2024; 9: 100098.     CrossRef
  • Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
    Joseph Henson, Aikaterina Tziannou, Alex V. Rowlands, Charlotte L. Edwardson, Andrew P. Hall, Melanie J. Davies, Thomas Yates
    Diabetes, Obesity and Metabolism.2024;[Epub]     CrossRef
  • The Current Landscape of Pharmacotherapies for Sarcopenia
    Gulistan Bahat, Serdar Ozkok
    Drugs & Aging.2024; 41(2): 83.     CrossRef
  • Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
    Elissa Driggin, Parag Goyal
    Journal of Cardiac Failure.2024;[Epub]     CrossRef
  • Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
    Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
    International Journal of Cardiology.2023; 370: 263.     CrossRef
  • Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
    Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
    Obesity.2023; 31(1): 74.     CrossRef
  • Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
    Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
    Diabetes, Obesity and Metabolism.2023; 25(4): 901.     CrossRef
  • The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
    Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
    Obesity Reviews.2023;[Epub]     CrossRef
  • Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
    Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
    Cardiovascular Diabetology.2023;[Epub]     CrossRef
  • Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
    Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies
    Diabetic Medicine.2023;[Epub]     CrossRef
  • Cancer cachexia as a blueprint for treating obesity
    Nikolai P. Jaschke, Tilman D. Rachner
    Trends in Endocrinology & Metabolism.2023; 34(7): 395.     CrossRef
  • The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
    Peter N. Benotti, Bruce R. Bistrian
    Surgery for Obesity and Related Diseases.2023; 19(9): 1075.     CrossRef
  • Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
    Cody Rutledge, Angela Enriquez, Kevin Redding, Mabel Lopez, Steven Mullett, Stacy L. Gelhaus, Michael Jurczak, Eric Goetzman, Brett A. Kaufman
    Cardiovascular Drugs and Therapy.2023;[Epub]     CrossRef
  • Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Cysteine‐lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose‐finding study
    Kathrine J. Vinknes, Thomas Olsen, Hasse Khiabani Zaré, Nasser E. Bastani, Emma Stolt, Anja F. Dahl, Roger D. Cox, Helga Refsum, Kjetil Retterstøl, Anders Åsberg, Amany Elshorbagy
    Diabetes, Obesity and Metabolism.2023; 25(11): 3161.     CrossRef
  • Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review
    Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
    Drugs & Aging.2023; 40(8): 703.     CrossRef
  • Introduction to the dietary management of obesity in adults
    Vivian Lee
    Clinical Medicine.2023; 23(4): 304.     CrossRef
  • Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
    Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino
    Diabetes, Obesity and Metabolism.2023; 25(12): 3538.     CrossRef
  • Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors
    Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi
    Circulation Journal.2023; 88(1): 10.     CrossRef
  • Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
    Baris Afsar, Rengin Elsurer Afsar
    Clinical Nutrition.2023; 42(12): 2338.     CrossRef
  • Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
    Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
    Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh
    Diabetes Therapy.2023; 14(12): 2015.     CrossRef
  • Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Chengdong Xia, Yufeng Han, Chunhui Yin, Ruyue Geng, Zhenfei Liu, Yongle Du, Mingkun Yu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
    Thomas A. Wadden, Ariana M. Chao, Molly Moore, Jena S. Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M. Jakicic
    Current Obesity Reports.2023; 12(4): 453.     CrossRef
  • Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
    Giuseppe Lisco, Olga Eugenia Disoteo, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Fabio Monzani, Emilio Jirillo, Renato Cozzi, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani
    Nutrients.2023; 16(1): 63.     CrossRef
  • Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
    Sabine Kahl, Jennifer Pützer, Michael Roden
    Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
  • Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
    Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
    Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
  • Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
    Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
    Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
  • Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
    Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
    Scientific Reports.2022;[Epub]     CrossRef
  • Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
    Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
    Obesity Reviews.2022;[Epub]     CrossRef
  • Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
    Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
    Expert Opinion on Drug Safety.2022; 21(10): 1315.     CrossRef
  • Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
    Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
    Expert Opinion on Drug Safety.2022; 21(11): 1411.     CrossRef
  • Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
    Lyse Bordier, Jean Doucet, Bernard Bauduceau
    Médecine des Maladies Métaboliques.2022; 16(5): 422.     CrossRef
  • Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
    Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
    Nutrition.2022; 103-104: 111815.     CrossRef
  • The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
    Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
    Medicines.2022; 9(9): 47.     CrossRef
  • Distribution of lean mass and mortality risk in patients with type 2 diabetes
    Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
    Primary Care Diabetes.2022; 16(6): 824.     CrossRef
  • Cardio-sarcopenia: A syndrome of concern in aging
    De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Type 2 diabetes
    Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
    The Lancet.2022; 400(10365): 1803.     CrossRef
  • Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
    Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
    Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
    Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
  • Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
    Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. le Roux
    Obesity.2021; 29(3): 529.     CrossRef
  • Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
    Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
    BMJ Open.2021; 11(4): e045844.     CrossRef
  • Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
    Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
    Cancer Prevention Research.2021; 14(5): 509.     CrossRef
  • Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
    Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
    Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
    Nutrition & Diabetes.2021;[Epub]     CrossRef
  • Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
    Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
    Drugs.2021; 81(11): 1243.     CrossRef
  • Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
    Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
  • Physical activity and exercise in the management of type 2 diabetes: where to start?
    Deirdre Harrington, Joe Henson
    Practical Diabetes.2021; 38(5): 35.     CrossRef
  • Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes

    New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
  • Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
    Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
    Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
  • Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
    Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
    Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
  • Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
    Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
    Nutrients.2020; 12(2): 510.     CrossRef
  • GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
    Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
    Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
  • Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
    Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
    Aging Cell.2020;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism